

## Supplementary Materials

Table S1. Predisposing factors for VTE in the study population.

	Whole cohort (n= 157)	VTE associated with COVID-19 (n=30)	VTE unrelated to COVID-19 (n=127)	p
<b><u>MAJOR risk factors</u></b>				
Fracture of the lower limbs or major trauma– <i>n (%)</i>	3 (1.9%)	0	3 (2.4%)	>0.999
Prior VTE (PE or DVT)– <i>n (%)</i>	23 (14.6%)	1 (3.3%)	22 (17.3%)	0.081
Spinal cord injury– <i>n (%)</i>	0	0	0	>0.999
Hospitalization due to congestive heart failure or atrial fibrillation/flutter (within 3 months)– <i>n (%)</i>	1 (0.6%)	0	1 (0.8%)	>0.999
Previous hip or knee replacement– <i>n (%)</i>	0	0	0	>0.999
Myocardial infarction (within 3 months)– <i>n (%)</i>	0	0	0	>0.999
<b><u>MODERATE risk factors</u></b>				
Arthroscopic surgery of the knee – <i>n (%)</i>	0	0	0	>0.999
Autoimmune disease– <i>n (%)</i>	17 (10.8%)	1 (3.3%)	16 (12.6%)	0.076
Blood transfusions– <i>n (%)</i>	0	0	0	>0.999
Central venous line– <i>n (%)</i>	2 (1.3%)	0	2 (1.6%)	>0.999
Intravenous catheter and electrocatheter– <i>n (%)</i>	2 (1.3%)	1 (3.3%)	1 (0.8%)	0.346
Chemotherapy– <i>n (%)</i>	11 (7%)	1 (3.3%)	10 (7.9%)	0.692
Congestive heart failure or respiratory failure – <i>n (%)</i>	12 (7.6%)	2 (6.7%)	10 (7.9%)	>0.999
Erythropoiesis-stimulating agents – <i>n (%)</i>	0	0	0	>0.999
Hormone replacement therapy– <i>n (%)</i>	1 (0.6%)	0	1 (0.8%)	>0.999
In vitro fertilization– <i>n (%)</i>	1 (0.6%)	0	1 (0.8%)	>0.999
Oral contraceptive therapy– <i>n (%)</i>	1 (0.6%)	0	1 (0.8%)	>0.999
Postpartum period– <i>n (%)</i>	0	0	0	>0.999
Infection (i.e. pneumonia, UTI)– <i>n (%)</i>	54 (34.4%)	27 (90%)	27 (21.3%)	<0.001
HIV– <i>n (%)</i>	3 (1.9%)	0	3 (2.4%)	>0.999
Inflammatory Bowel Disease– <i>n (%)</i>	2 (1.3%)	1 (3.3%)	1 (0.8%)	0.346
Cancer (highest risk in metastatic disease) – <i>n (%)</i>	35 (22.3%)	3 (10%)	32 (25.2%)	0.089
Paralytic stroke– <i>n (%)</i>	0	0	0	>0.999
Superficial vein thrombosis– <i>n (%)</i>	4 (2.5%)	0	4 (3.1%)	>0.999
Thrombophilia– <i>n (%)</i>	3 (1.9%)	0	3 (2.4%)	>0.999
<b><u>MINOR risk factors</u></b>				
Bed rest> 3 days– <i>n (%)</i>	7 (4.5%)	2 (6.7%)	5 (3.9%)	0.619

<b>Diabetes – <i>n</i> (%)</b>	22 (14%)	2 (6.7%)	20 (12.7%)	0.253
<b>Hypertension - <i>n</i> (%)</b>	85 (54.1%)	17 (56%)	68 (53.5%)	0.839
<b>Immobility due to circumstances (i.e prolonged travel by plane or car)– <i>n</i> (%)</b>	0	0	0	>0.999
<b>Age&gt; 65 – <i>n</i> (%)</b>	94 (59.9%)	17 (56.7%)	77 (60.6%)	0.685
<b>Laparoscopic surgery (i.e. cholecystectomy)– <i>n</i> (%)</b>	1 (0.6%)	0	1 (0.8%)	>0.999
<b>Obesity– <i>n</i> (%)</b>	20 (12.7%)	5 (16.7%)	15 (11.8%)	0.542
<b>Pregnancy– <i>n</i> (%)</b>	0	0	0	>0.999
<b>Varicose veins– <i>n</i> (%)</b>	12 (7.6%)	1 (3.3%)	11 (8.7%)	0.464

VTE = venous thromboembolism, PE = pulmonary embolism, DVT = deep vein thrombosis, UTI = urinary tract infection.

**Table S2.** Characteristics of the compression ultrasound examination assessment.

CUS	Whole cohort	VTE associated with COVID-19	VTE unrelated to COVID-19	p
<b><u>Baseline</u></b>	<b>n=84 (53.5%)</b>	<b>n=14 (46.67%)</b>	<b>n=70 (55.12%)</b>	
No DVT	41 (48.81%)	13 (92.86%)	28 (40%)	<b>0.001</b>
Partial thrombosis	13 (15.47%)	0	13 (18.57%)	
Occlusive thrombosis	30 (35.71%)	1 (7.14%)	29 (41.43%)	
<b><u>1 month</u></b>	<b>n= 27 (17.19%)</b>	<b>n=3 (10%)</b>	<b>n=24 (18.89%)</b>	
No DVT	18 (66.67%)	2 (66.66%)	16 (66.67%)	0.755
Partial thrombosis	6 (22.22%)	1 (33.33%)	5 (20.83%)	
Occlusive thrombosis	3 (11.11%)	0	3 (12.5%)	
<b><u>3 months</u></b>	<b>n=21 (13.37%)</b>	<b>n=3 (10%)</b>	<b>n=18 (14.17%)</b>	
No DVT	17 (80.95%)	3 (100%)	14 (77.78%)	0.662
Partial thrombosis	3 (14.28%)	0	3 (16.67%)	
Occlusive thrombosis	1 (4.76%)	0	1 (5.56%)	
<b><u>6 months</u></b>	<b>n=12 (7.64%)</b>	<b>n=0</b>	<b>n=12 (10.72%)</b>	
No DVT	7 (58.33%)	0	7 (58.33%)	na
Partial thrombosis	3 (25%)	0	3 (25%)	
Occlusive thrombosis	2 (16.67%)	0	2 (16.67%)	
<b><u>12 months</u></b>	<b>n=3 (1.91%)</b>	<b>n=0</b>	<b>n=3 (2.36%)</b>	
No DVT	1 (33.33%)	0	1 (33.33%)	na
Partial thrombosis	2 (66.66%)	0	2 (66.66%)	
Occlusive thrombosis	0	0	0	
<b><u>18 months</u></b>	<b>n=3 (1.91%)</b>	<b>n=0</b>	<b>n=3 (2.36%)</b>	
No DVT	2 (66.66%)	0	2 (66.66%)	na
Partial thrombosis	0	0	0	
Occlusive thrombosis	1 (33.33%)	0	1 (33.33%)	
<b><u>24 months</u></b>	<b>n=2 (11.76%)</b>	<b>n=0</b>	<b>n=2 (1.57%)</b>	
No DVT	1 (50%)	0	1 (50%)	na
Partial thrombosis	1 (50%)	0	1 (50%)	
Occlusive thrombosis	0	0	0	

CUS, compression ultrasound; DVT, deep vein thrombosis

Table S3. VTE BLEED score during the study time points.

	Whole cohort	VTE associated with COVID-19	VTE unrelated to COVID-19	p
<b><u>Baseline</u></b>	<b>n=157</b>	<b>n=30</b>	<b>n=127</b>	
Low risk– n (%)	82 (52.23%)	18 (60%)	64 (50.39%)	0.417
High risk– n (%)	75 (47.77%)	12 (40%)	63 (49.61%)	
<b><u>1 month</u></b>	<b>n=145 (92.36%)</b>	<b>n=27 (90%)</b>	<b>n=118 (92.91%)</b>	
Low risk– n (%)	76 (52.41%)	14 (51.85%)	62 (52.54%)	>0.999
High risk– n (%)	69 (47.59%)	13 (48.15%)	56 (47.46%)	
<b><u>3 months</u></b>	<b>n=96 (61.15%)</b>	<b>n=24 (80%)</b>	<b>n=72 (56.69%)</b>	
Low risk– n (%)	56 (58.33%)	16 (66.67%)	40 (55.56%)	0.474
High risk– n (%)	40 (41.67%)	8 (33.33%)	32 (44.44%)	
<b><u>6 months</u></b>	<b>n=73 (46.5%)</b>	<b>n=19 (63.33%)</b>	<b>n=54 (42.52%)</b>	
Low risk– n (%)	46 (63.01%)	16 (84.21%)	30 (55.56%)	0.0298
High risk– n (%)	27 (23.99%)	3 (15.79%)	24 (44.44%)	
<b><u>12 months</u></b>	<b>n=36 (22.92%)</b>	<b>n=7 (23.33%)</b>	<b>n=29 (22.83%)</b>	
Low risk– n (%)	23 (63.89%)	5 (71.43%)	18 (62.07%)	>0.999
High risk– n (%)	13 (36.11%)	2 (28.57%)	11 (37.93%)	
<b><u>18 months</u></b>	<b>n=21 (13.38%)</b>	<b>n=2 (6.67%)</b>	<b>n=19 (14.96%)</b>	
Low risk– n (%)	13 (61.9%)	2 (100%)	11 (57.9%)	0.505
High risk– n (%)	8 (38.1%)	0	8 (42.1%)	
<b><u>24 months</u></b>	<b>n=12 (7.64%)</b>	<b>n=2 (6.67%)</b>	<b>n=10 (7.87%)</b>	
Low risk– n (%)	7 (58.33%)	2 (100%)	5 (50%)	0.470
High risk– n (%)	5 (41.66%)	0	5 (50%)	

Table S4. Signs of pulmonary hypertension at trans-thoracic echocardiography in the first six-months.

	Whole cohort	VTE associated with COVID-19	VTE unrelated to COVID-19	p
<b>Baseline</b>	17/94 (18.08%)	1/15 (6.67%)	16/79 (20.25%)	0.291
<b>3 months</b>	6 /45 (13.33%)	1/15 (6.67%)	5/79 (16.67%)	0.647
<b>6 months</b>	7 /18(38.89%)	0/4	7 /14(50%)	0.119